Skip to Content
MDPIMDPI
ARMAdvances in Respiratory Medicine
PDF
  • Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
  • Case Report
  • Open Access

27 January 2022

Steroids in COVID-19: Tailor-Made or “One Size Fits All”?

and
All India Institute of Medical Sciences, Delhi, India
*
Author to whom correspondence should be addressed.
Adv. Respir. Med.2022, 90(1), 94-96;https://doi.org/10.5603/ARM.a2022.0005
Version Notes
Order Reprints

Abstract

Since the RECOVERY trial, steroids have endorsed by all Guideliness for treating moderate-severe COVID-19. The prescribed dose is 6mg dexamethasone or its equivalents for 10 days. However, in clinical practice, there are numerous occasions where the role of steroids cannot be extrapolated from current evidence: patients on immunosuppression, patients with persistent oxygen requirement after ten days of therapy, etc. We highlight the existing caveats and the need for further research and discussion.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
The Effect of Albuterol with Heliox versus Albuterol Nebulization in Acute Asthma Exacerbation: A Randomized Controlled Clinical Trial
Previous
Interleukin-26 is Associated with the Level of Systemic Inflammation and Lung Functions in Obese and Non-obese Moderate-to-Severe Asthmatic Patients
Next